Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst1996 ; 88 : 1456 –66.
Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. for the American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol2001 ; 19 : 1865 –78.
Schilsky RL and Taube SE. Introduction: Tumor markers as clinical cancer tests—are we there yet? Semin Oncol2002 ; 29 : 211 –2.
McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst1991 ; 83 : 154 –5.
Fielding LP, Fenoglio-Preiser CM, and Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer1992 ; 70 : 2367 –77.
Burke HB, Henson DE. Criteria for prognostic factors and for an enhanced prognostic system. Cancer1993 ; 72 : 3131 –5.
Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med1993 ; 118 : 201 –10.
Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst1993 ; 85 : 1206 –19.
Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer1994 ; 69 : 979 –85.
Gasparini G. Prognostic variables in node-negative and node-positive breast cancer. Breast Cancer Res Treat1998 ; 52 : 321 –31.
Hall PA, Going JJ. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology1999 ; 35 : 489 –94.
Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol2002 ; 12 : 1 –6.
Thor AD, Liu S, Moore DH II, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol1999 ; 17 : 470 –7.
Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, DiLeo A, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol2000 ; 113 : 675 –82.
McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, et al., and the National Cancer Institute Bladder Tumor Marker Network. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res2000 ; 6 : 1854 –64.
Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst2002 ; 94 : 852 –4.
Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst2002 ; 94 : 855 –7.
Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer1995 ; 72 : 511 –8.
Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest2002 ; 122 : 1037 –57.
Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg2002 ; 235 : 10 –26.
Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer2003 ; 88 : 1191 –8.
Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer2003 ; 39 : 19 –30.
Burton A, Altman DG. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer2004 ; 91 : 4 –8.
Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol2004 ; 22 : 529 –36.
Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res2004 ; 10 : 4 –12.
Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat1998 ; 52 : 289 –303.
Gion M, Boracchi P, Biganzoli E, Daidone MG. A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers). Int J Biol Markers1999 ; 14 : 123 –33.
Altman DG. Systematic reviews of evaluations of prognostic variables. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. 2nd ed. London (UK): BMJ Books; 2001 . p. 228–47.
McShane LM, Simon R. Statistical methods for the analysis of prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RV, O'Sullivan B, Sobin LH, Wittekind Ch, editors. Prognostic factors in cancer. 2nd ed. New York (NY): Wiley-Liss; 2001 . p. 37–48.
Simon R. Evaluating prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RV, O'Sullivan B, Sobin LH, Wittekind Ch, editors. Prognostic factors in cancer. 2nd ed. New York (NY): Wiley-Liss; 2001 . p. 49–56.
Biganzoli E, Boracchi P, Marubini E. Biostatistics and tumor marker studies in breast cancer: Design, analysis and interpretation issues. Int J Biol Markers2003 ; 18 : 40 –8.
Schumacher M, Hollander N, Schwarzer G, Sauerbrei W. Prognostic factor studies. In: Crowley J, editor. Handbook of statistics in clinical oncology. New York (NY): CRC Press; 2005 . p. 307–51.
Moher D, Schulz KF, Altman D for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA2001 ; 285 : 1987 –91.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem2003 ; 49 : 1 –6.
Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst1994 ; 86 : 829 –35.
Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat1992 ; 22 : 197 –206.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D for the QUOROM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet1999 ; 354 : 1896 –900.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA2000 ; 283 : 2008 –12.
Hammond ME, Taube SE. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol2002 ; 29 : 213 –21.
Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med2001 ; 134 : 663 –94.